Copyright Reports & Markets. All rights reserved.

Global Hereditary Angioedema Therapeutic Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Hereditary Angioedema Therapeutic
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Hereditary Angioedema Therapeutic by Type
    • 1.3.1 Overview: Global Hereditary Angioedema Therapeutic Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Hereditary Angioedema Therapeutic Consumption Value Market Share by Type in 2023
    • 1.3.3 Intravenous
    • 1.3.4 Subcutaneous
    • 1.3.5 Oral
  • 1.4 Global Hereditary Angioedema Therapeutic Market by Application
    • 1.4.1 Overview: Global Hereditary Angioedema Therapeutic Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospitals
    • 1.4.3 Clinics
    • 1.4.4 Others
  • 1.5 Global Hereditary Angioedema Therapeutic Market Size & Forecast
  • 1.6 Global Hereditary Angioedema Therapeutic Market Size and Forecast by Region
    • 1.6.1 Global Hereditary Angioedema Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Hereditary Angioedema Therapeutic Market Size by Region, (2019-2030)
    • 1.6.3 North America Hereditary Angioedema Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Hereditary Angioedema Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Hereditary Angioedema Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.6 South America Hereditary Angioedema Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Hereditary Angioedema Therapeutic Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 BioCryst Pharma
    • 2.1.1 BioCryst Pharma Details
    • 2.1.2 BioCryst Pharma Major Business
    • 2.1.3 BioCryst Pharma Hereditary Angioedema Therapeutic Product and Solutions
    • 2.1.4 BioCryst Pharma Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 BioCryst Pharma Recent Developments and Future Plans
  • 2.2 Ionis Pharma
    • 2.2.1 Ionis Pharma Details
    • 2.2.2 Ionis Pharma Major Business
    • 2.2.3 Ionis Pharma Hereditary Angioedema Therapeutic Product and Solutions
    • 2.2.4 Ionis Pharma Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Ionis Pharma Recent Developments and Future Plans
  • 2.3 Pharming Group
    • 2.3.1 Pharming Group Details
    • 2.3.2 Pharming Group Major Business
    • 2.3.3 Pharming Group Hereditary Angioedema Therapeutic Product and Solutions
    • 2.3.4 Pharming Group Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Pharming Group Recent Developments and Future Plans
  • 2.4 CSL Limited
    • 2.4.1 CSL Limited Details
    • 2.4.2 CSL Limited Major Business
    • 2.4.3 CSL Limited Hereditary Angioedema Therapeutic Product and Solutions
    • 2.4.4 CSL Limited Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 CSL Limited Recent Developments and Future Plans
  • 2.5 Shire
    • 2.5.1 Shire Details
    • 2.5.2 Shire Major Business
    • 2.5.3 Shire Hereditary Angioedema Therapeutic Product and Solutions
    • 2.5.4 Shire Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Shire Recent Developments and Future Plans
  • 2.6 Attune Pharma
    • 2.6.1 Attune Pharma Details
    • 2.6.2 Attune Pharma Major Business
    • 2.6.3 Attune Pharma Hereditary Angioedema Therapeutic Product and Solutions
    • 2.6.4 Attune Pharma Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Attune Pharma Recent Developments and Future Plans
  • 2.7 Adverum Biotechnologies
    • 2.7.1 Adverum Biotechnologies Details
    • 2.7.2 Adverum Biotechnologies Major Business
    • 2.7.3 Adverum Biotechnologies Hereditary Angioedema Therapeutic Product and Solutions
    • 2.7.4 Adverum Biotechnologies Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Adverum Biotechnologies Recent Developments and Future Plans
  • 2.8 KalVista Pharma
    • 2.8.1 KalVista Pharma Details
    • 2.8.2 KalVista Pharma Major Business
    • 2.8.3 KalVista Pharma Hereditary Angioedema Therapeutic Product and Solutions
    • 2.8.4 KalVista Pharma Hereditary Angioedema Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 KalVista Pharma Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Hereditary Angioedema Therapeutic Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Hereditary Angioedema Therapeutic by Company Revenue
    • 3.2.2 Top 3 Hereditary Angioedema Therapeutic Players Market Share in 2023
    • 3.2.3 Top 6 Hereditary Angioedema Therapeutic Players Market Share in 2023
  • 3.3 Hereditary Angioedema Therapeutic Market: Overall Company Footprint Analysis
    • 3.3.1 Hereditary Angioedema Therapeutic Market: Region Footprint
    • 3.3.2 Hereditary Angioedema Therapeutic Market: Company Product Type Footprint
    • 3.3.3 Hereditary Angioedema Therapeutic Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Hereditary Angioedema Therapeutic Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Hereditary Angioedema Therapeutic Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Hereditary Angioedema Therapeutic Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Hereditary Angioedema Therapeutic Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Hereditary Angioedema Therapeutic Consumption Value by Type (2019-2030)
  • 6.2 North America Hereditary Angioedema Therapeutic Consumption Value by Application (2019-2030)
  • 6.3 North America Hereditary Angioedema Therapeutic Market Size by Country
    • 6.3.1 North America Hereditary Angioedema Therapeutic Consumption Value by Country (2019-2030)
    • 6.3.2 United States Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Hereditary Angioedema Therapeutic Consumption Value by Type (2019-2030)
  • 7.2 Europe Hereditary Angioedema Therapeutic Consumption Value by Application (2019-2030)
  • 7.3 Europe Hereditary Angioedema Therapeutic Market Size by Country
    • 7.3.1 Europe Hereditary Angioedema Therapeutic Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.3 France Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Hereditary Angioedema Therapeutic Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Hereditary Angioedema Therapeutic Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Hereditary Angioedema Therapeutic Market Size by Region
    • 8.3.1 Asia-Pacific Hereditary Angioedema Therapeutic Consumption Value by Region (2019-2030)
    • 8.3.2 China Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.5 India Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Hereditary Angioedema Therapeutic Consumption Value by Type (2019-2030)
  • 9.2 South America Hereditary Angioedema Therapeutic Consumption Value by Application (2019-2030)
  • 9.3 South America Hereditary Angioedema Therapeutic Market Size by Country
    • 9.3.1 South America Hereditary Angioedema Therapeutic Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Hereditary Angioedema Therapeutic Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Hereditary Angioedema Therapeutic Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Hereditary Angioedema Therapeutic Market Size by Country
    • 10.3.1 Middle East & Africa Hereditary Angioedema Therapeutic Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Hereditary Angioedema Therapeutic Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Hereditary Angioedema Therapeutic Market Drivers
  • 11.2 Hereditary Angioedema Therapeutic Market Restraints
  • 11.3 Hereditary Angioedema Therapeutic Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Hereditary Angioedema Therapeutic Industry Chain
  • 12.2 Hereditary Angioedema Therapeutic Upstream Analysis
  • 12.3 Hereditary Angioedema Therapeutic Midstream Analysis
  • 12.4 Hereditary Angioedema Therapeutic Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Hereditary Angioedema Therapeutic market size was valued at USD 2149.1 million in 2023 and is forecast to a readjusted size of USD 3000 million by 2030 with a CAGR of 4.9% during review period.
    Hereditary Angioedema Therapeutic is the treatment for Hereditary Angioedema. Growing cases of hereditary angioedema (HAE) globally is a key market driver.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    The Global Info Research report includes an overview of the development of the Hereditary Angioedema Therapeutic industry chain, the market status of Hospitals (Intravenous, Subcutaneous), Clinics (Intravenous, Subcutaneous), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Hereditary Angioedema Therapeutic.
    Regionally, the report analyzes the Hereditary Angioedema Therapeutic markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Hereditary Angioedema Therapeutic market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Hereditary Angioedema Therapeutic market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Hereditary Angioedema Therapeutic industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Intravenous, Subcutaneous).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Hereditary Angioedema Therapeutic market.
    Regional Analysis: The report involves examining the Hereditary Angioedema Therapeutic market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Hereditary Angioedema Therapeutic market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Hereditary Angioedema Therapeutic:
    Company Analysis: Report covers individual Hereditary Angioedema Therapeutic players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Hereditary Angioedema Therapeutic This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Clinics).
    Technology Analysis: Report covers specific technologies relevant to Hereditary Angioedema Therapeutic. It assesses the current state, advancements, and potential future developments in Hereditary Angioedema Therapeutic areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Hereditary Angioedema Therapeutic market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Hereditary Angioedema Therapeutic market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    Intravenous
    Subcutaneous
    Oral
    Market segment by Application
    Hospitals
    Clinics
    Others
    Market segment by players, this report covers
    BioCryst Pharma
    Ionis Pharma
    Pharming Group
    CSL Limited
    Shire
    Attune Pharma
    Adverum Biotechnologies
    KalVista Pharma
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Hereditary Angioedema Therapeutic product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Hereditary Angioedema Therapeutic, with revenue, gross margin and global market share of Hereditary Angioedema Therapeutic from 2019 to 2024.
    Chapter 3, the Hereditary Angioedema Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Hereditary Angioedema Therapeutic market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Hereditary Angioedema Therapeutic.
    Chapter 13, to describe Hereditary Angioedema Therapeutic research findings and conclusion.

    Buy now